Skip to Content
Merck
  • Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.

Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.

Cancer cell (2023-04-22)
Sujata Jana, Sandipan Brahma, Sonali Arora, Cynthia L Wladyka, Patrick Hoang, Steven Blinka, Rowan Hough, Jessie L Horn, Yuzhen Liu, Li-Jie Wang, Philippe Depeille, Eric Smith, Robert B Montgomery, John K Lee, Michael C Haffner, Funda Vakar-Lopez, Petros Grivas, Jonathan L Wright, Hung-Ming Lam, Peter C Black, Jeroen P Roose, Alexey G Ryazanov, Arvind R Subramaniam, Steven Henikoff, Andrew C Hsieh
ABSTRACT

We uncover a tumor-suppressive process in urothelium called transcriptional-translational conflict caused by deregulation of the central chromatin remodeling component ARID1A. Loss of Arid1a triggers an increase in a nexus of pro-proliferation transcripts, but a simultaneous inhibition of the eukaryotic elongation factor 2 (eEF2), which results in tumor suppression. Resolution of this conflict through enhancing translation elongation speed enables the efficient and precise synthesis of a network of poised mRNAs resulting in uncontrolled proliferation, clonogenic growth, and bladder cancer progression. We observe a similar phenomenon in patients with ARID1A-low tumors, which also exhibit increased translation elongation activity through eEF2. These findings have important clinical implications because ARID1A-deficient, but not ARID1A-proficient, tumors are sensitive to pharmacologic inhibition of protein synthesis. These discoveries reveal an oncogenic stress created by transcriptional-translational conflict and provide a unified gene expression model that unveils the importance of the crosstalk between transcription and translation in promoting cancer.

MATERIALS
Product Number
Brand
Product Description

Roche
cOmplete, Mini Protease Inhibitor Cocktail, Tablets provided in a glass vial
Sigma-Aldrich
Anti-ARID1A antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Y-27632 dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Hydrocortisone, ≥98% (HPLC)
Sigma-Aldrich
Cycloheximide, from microbial, ≥94% (TLC)
Sigma-Aldrich
Anti-α-Tubulin antibody, Mouse monoclonal, clone AA13, purified from hybridoma cell culture
Sigma-Aldrich
N-Acetyl-L-cysteine, BioReagent, suitable for cell culture
Sigma-Aldrich
Tamoxifen, ≥99%
Sigma-Aldrich
Anti-acetyl-Histone H3 (Lys27) Antibody, clone RM172, clone RM172, from rabbit
Sigma-Aldrich
eEF2K Inhibitor, A-484954, The eEF2K Inhibitor, A-484954, also referenced under CAS 142557-61-7, controls the biological activity of eEF2K Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.
Sigma-Aldrich
Anti-Puromycin Antibody, clone 12D10, clone 12D10, from mouse